Literature DB >> 30067889

Increasing Liver Transplantation Wait-List Dropout for Hepatocellular Carcinoma With Widening Geographical Disparities: Implications for Organ Allocation.

Neil Mehta1, Jennifer L Dodge2, Ryutaro Hirose2, John P Roberts2, Francis Y Yao1,2.   

Abstract

Given the increasing incidence of hepatocellular carcinoma (HCC) and regional variation in liver transplantation (LT) rates for HCC, we investigated temporal and geographic disparities in LT and wait-list dropout. LT candidates receiving Model for End-Stage Liver Disease (MELD) exception from 2005 to 2014 were identified from the United Network for Organ Sharing database (n = 14,320). Temporal differences were compared across 2 eras (2005-2009 and 2010-2014). Regional groups were defined based on median wait time as long-wait region (LWR; regions 1, 5, and 9), mid-wait region (MWR; regions 2, 4, 6, 7, and 8), and short-wait region (SWR; regions 3, 10, and 11). Fine and Gray competing risk regression estimated risk of wait-list dropout as hazard ratios (HRs). The cumulative probability of LT within 3 years was 70% in the LWR versus 81% in the MWR and 91% in the SWR (P < 0.001). From 2005-2009 to 2010-2014, median time to LT increased by 6.0 months (5.6 to 11.6 months) in the LWR compared with 3.8 months (2.6 to 6.4 months) in the MWR and 1.3 months (1.0 to 2.3 months) in the SWR. The cumulative probability of dropout within 3 years was 24% in the LWR versus 16% in the MWR and 8% in the SWR (P < 0.001). From 2005-2009 to 2010-2014, the LWR also had the greatest increase in probability of dropout. Risk of dropout was increased in the LWR (HR, 3.5; P < 0.001) and the MWR (HR, 2.2; P < 0.001) compared with the SWR, and year of MELD exception 2010-2014 (HR, 1.9; P < 0.001) compared with 2005-2009. From 2005-2009 to 2010-2014, intention-to-treat 3-year survival decreased from 69% to 63% in the LWR (P < 0.001), 72% to 69% in the MWR (P = 0.008), and remained at 74% in the SWR (P = 0.48). In conclusion, we observed a significant increase in wait-list dropout in HCC patients in recent years that disproportionately impacted LWR patients. Widening geographical disparities call for changes in allocation policy as well as enhanced efforts at increasing organ donation and utilization.
© 2018 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2018        PMID: 30067889      PMCID: PMC6445639          DOI: 10.1002/lt.25317

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  11 in total

1.  Shorter Height Is Associated With Lower Probability of Liver Transplantation in Patients With Hepatocellular Carcinoma.

Authors:  Eric Lee; Monika Sarkar; Jennifer Dodge; Maureen Kohi; Neil Mehta
Journal:  Transplantation       Date:  2020-05       Impact factor: 4.939

2.  Impact of Payer Status on Delisting Among Liver Transplant Candidates in the United States.

Authors:  Krystal L Karunungan; Yas Sanaiha; Roland A Hernandez; Holly Wilhalme; Sarah Rudasill; Joseph Hadaya; Joseph DiNorcia; Peyman Benharash
Journal:  Liver Transpl       Date:  2020-12-31       Impact factor: 5.799

3.  The Impact of Median Model for End-Stage Liver Disease at Transplant Minus 3 National Policy on Waitlist Outcomes in Patients With and Without Hepatocellular Carcinoma.

Authors:  Sarah Bernards; Ryutaro Hirose; Francis Y Yao; Chengshi Jin; Jennifer L Dodge; Chiung-Yu Huang; Neil Mehta
Journal:  Liver Transpl       Date:  2021-12-08       Impact factor: 5.799

4.  Living donor liver transplantation or hepatic resection combined with intraoperative radiofrequency ablation for Child-Pugh A hepatocellular carcinoma patient with Multifocal Tumours Meeting the University of California San Francisco (UCSF) criteria.

Authors:  Xi Xu; Xingyu Pu; Li Jiang; Yang Huang; Lunan Yan; Jiayin Yang; Tianfu Wen; Bo Li; Hong Wu; Wentao Wang
Journal:  J Cancer Res Clin Oncol       Date:  2020-08-27       Impact factor: 4.553

5.  A novel waitlist dropout score for hepatocellular carcinoma - identifying a threshold that predicts worse post-transplant survival.

Authors:  Neil Mehta; Jennifer L Dodge; John P Roberts; Francis Y Yao
Journal:  J Hepatol       Date:  2020-11-11       Impact factor: 25.083

6.  Comparison of Liver Transplant Wait-List Outcomes Among Patients With Hepatocellular Carcinoma With Public vs Private Medical Insurance.

Authors:  Liat Gutin; Francis Yao; Jennifer L Dodge; Joshua Grab; Neil Mehta
Journal:  JAMA Netw Open       Date:  2019-08-02

7.  Unfair Advantages for Hepatocellular Carcinoma Patients Listed for Liver Transplant in Short-Wait Regions Following 2015 Hepatocellular Carcinoma Policy Change.

Authors:  Max N Brondfield; Jennifer L Dodge; Ryutaro Hirose; Julie Heimbach; Francis Y Yao; Neil Mehta
Journal:  Liver Transpl       Date:  2020-05       Impact factor: 5.799

8.  Downstaging Outcomes for Hepatocellular Carcinoma: Results From the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) Consortium.

Authors:  Neil Mehta; Catherine Frenette; Parissa Tabrizian; Maarouf Hoteit; Jennifer Guy; Neehar Parikh; T Tara Ghaziani; Renu Dhanasekaran; Jennifer L Dodge; Brahma Natarajan; Matthew L Holzner; Leana Frankul; Wesley Chan; Austin Fobar; Sander Florman; Francis Y Yao
Journal:  Gastroenterology       Date:  2021-07-28       Impact factor: 22.682

9.  Cost-Effectiveness of Hepatocellular Carcinoma Surveillance: An Assessment of Benefits and Harms.

Authors:  Neehar D Parikh; Amit G Singal; David W Hutton; Elliot B Tapper
Journal:  Am J Gastroenterol       Date:  2020-10       Impact factor: 12.045

10.  Donation After Circulatory Death Is Associated With Similar Posttransplant Survival in All but the Highest-Risk Hepatocellular Carcinoma Patients.

Authors:  Jordyn Silverstein; Garrett Roll; Jennifer L Dodge; Joshua D Grab; Francis Y Yao; Neil Mehta
Journal:  Liver Transpl       Date:  2020-07-21       Impact factor: 5.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.